Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR3289(2)] to TBX1 - BSA and Azide free
- Suitable for: WB
- Reacts with: Mouse, Rat, Human
Product nameAnti-TBX1 antibody [EPR3289(2)] - BSA and Azide free
See all TBX1 primary antibodies
DescriptionRabbit monoclonal [EPR3289(2)] to TBX1 - BSA and Azide free
Tested applicationsSuitable for: WBmore details
Unsuitable for: Flow Cyt,ICC or IHC-P
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human TBX1 aa 100-200. The exact sequence is proprietary.
Ab239967 is the carrier-free version of ab109313. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.
Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
ab239967 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.
Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C. Do Not Freeze.
Storage bufferpH: 7.2
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab239967 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent concentration. Detects a band of approximately 43 kDa (predicted molecular weight: 43 kDa).|
FunctionProbable transcriptional regulator involved in developmental processes. Is required for normal development of the pharyngeal arch arteries.
Involvement in diseaseHaploinsufficiency of the TBX1 gene is responsible for most of the physical malformations present in DiGeorge syndrome (DGS) and velocardiofacial syndrome (VCFS) [MIM:188400, 192430]. DGS is characterized by the association of several malformations: hypoplastic thymus and parathyroid glands, congenital conotruncal cardiopathy, and a subtle but characteristic facial dysmorphology. VCFS is marked by the association of congenital conotruncal heart defects, cleft palate or velar insufficiency, facial dysmorpholgy and learning difficulties. It is now accepted that these two syndromes represent two forms of clinical expression of the same entity manifesting at different stages of life.
Defects in TBX1 are a cause of DiGeorge syndrome (DGS) [MIM:188400].
Defects in TBX1 are a cause of velocardiofacial syndrome (VCFS) [MIM:192430].
Defects in TBX1 are a cause of conotruncal heart malformations (CTHM) [MIM:217095]. CTHM consist of cardiac outflow tract defects, such as tetralogy of Fallot, pulmonary atresia, double-outlet right ventricle, truncus arteriosus communis, and aortic arch anomalies.
Sequence similaritiesContains 1 T-box DNA-binding domain.
- Information by UniProt
- Brachyury antibody
- CAFS antibody
- CTHM antibody
All lanes : Anti-TBX1 antibody [EPR3289(2)] (ab109313) at 1/1000 dilution
Lane 1 : PC12 lysate
Lane 2 : F9 lysate
Lane 3 : Neuro-2a lysate
Lane 4 : Jurkat lysate
Lane 5 : NCCIT lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 43 kDa
Observed band size: 43 kDa
This data was developed using ab109313, the same antibody clone in a different buffer formulation.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab239967 has not yet been referenced specifically in any publications.